Prostate And Other Male Cancers

NDA Submitted for Novel Non-Metastatic CRPC Treatment

By October 11, 2017

Apalutamide, an investigational, next generation oral androgen receptor inhibitor, was assessed for safety and efficacy in the Phase 3 pivotal trial, ARN-509-003 (SPARTAN), which the NDA is based on.

Cancer Survival for Alternative vs. Usual Treatment Examined

August 18, 2017

Alternative medicine was independently associated with greater risk of death compared with conventional cancer treatment overall (hazard ratio [HR], 2.50), as well as in subgroups with breast (HR, 5.68), lung (HR, 2.17), and colorectal cancer (HR, 4.57).

Genetics Should Play a Bigger Role in Clinical Decision-Making

June 21, 2017

As home genetic testing grows, patients will be bringing their results to physicians for reaction and response. Physicians will need to be proactively prepared.

Efficacy of Abiraterone Examined in Newly Diagnosed Prostate CA

June 06, 2017

Researchers of 2 newly published studies found that abiraterone (Zytiga) lowers risk of death by nearly 40% when added to standard androgen deprivation therapy.

Existing Treatment Effective in Bile Duct CA Following Surgery

May 22, 2017

In the per-protocol analysis, the researchers found that the average survival after surgery for those receiving capecitabine was 53 months, compared to 36 months for those who only had surgery. Existing Treatment Should be Considered Standard of Care in Biliary Cancer

Study Examines ACA Impact on Early Cancer Detection

May 19, 2017

For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.

New Zytiga Tablet Strength Available

By May 17, 2017

Zytiga was shown to lower serum testosterone and other androgens in patients enrolled in a Phase 3 placebo-controlled trial.

AUA 'Choosing Wisely' List IDs Unnecessary Tests, Treatments

By May 15, 2017

The 2017 AUA list contains evidence-based recommendations to guide conversations between physicians and patients about what care is appropriate.

Italian-Style Coffee Consumption May Reduce Prostate Cancer Risk

By April 26, 2017

Nearly 7,000 Italian men participating in the Moli-sani epidemiological study aged ≥50 years were monitored for an average of 4.25 years.

Prostate-Specific Antigen Testing Patterns Examined

April 25, 2017

In 2012 the USPSTF recommended against PSA testing for men of all ages.

Distinction Between Cancer Occurrence in U.S.-, African-Born Blacks

April 14, 2017

Research suggests differences in environmental, cultural, social, genetic factors

USPSTF Drafts Prostate CA Screening Recommendations

By April 11, 2017

The USPSTF performed a systematic review of the existing evidence and concluded that the potential benefits and harms of prostate-specific antigen (PSA)-based screening are "closely balanced" in men aged 55-69 years.

Overall Survival Examined for Adjunct Metformin Use in Prostate CA

April 11, 2017

The researchers found that survival curves showed that metformin use with docetaxel did not significantly improve prostate cancer-specific survival.

Environmental Toxins Linked to Multiple Diseases, Early Puberty

By April 07, 2017

These studies identified links to increased risks of thyroid, testicular and breast cancer, nonalcoholic fatty liver disease and even the early onset of puberty for boys, which can lead to diseases in adulthood.

Sleep Duration May Affect Prostate Cancer Mortality

April 04, 2017

Six hours of sleep a night was linked to a 29% higher risk of prostate cancer death compared to 7 hours. Men who were 65 or older showed no difference in the risk of death from prostate cancer.

Aspirin Use Linked to Reduced Risk of Cancer Death

April 04, 2017

The researchers found that regular aspirin use correlated with reduced risk of total mortality compared with nonregular use (multivariable-adjusted relative risks [RRs], 0.93 and 0.89 for women and men, respectively).

Androgen Deprivation Tx and Dementia: Is There a Link?

By March 30, 2017

Researchers analyzed the outcome of dementia among prostate cancer patients exposed to ADT vs. a lesser-exposed comparison group.

Pros and Cons of MRI versus Biopsy for Prostate CA Screening

March 28, 2017

The detection rate of high-grade prostate cancer was comparable for 6-TRUS-Bx, 12-TRUS-Bx, and MRI ± TBx; 10, 12, and 11%, respectively.

Are Antiemetic Prophylactics Being Overprescribed for Chemotherapy?

By March 24, 2017

Study authors identified a total of 8,545 patients undergoing 73,577 administrations of chemotherapy with minimal or low emetic risk.

Sexual Function Adverse Effects Assessed Among Prostate CA Therapies

March 22, 2017

The researchers found that the adjusted mean sexual domain score decreased more for radical prostatectomy than for EBRT at three years.

Alopecia, BPH Treatments Linked to PED

By March 09, 2017

Among those who developed PED, the condition continued for months or years, despite patients stopping treatment.

Bicalutamide Improves Survival in Recurrent Prostate Cancer

February 02, 2017

Fewer bicalutamide patients died of prostate cancer compared to patients taking placebo

Multi-Parametic MRI May Significantly Reduce Unnecessary Biopsies

January 23, 2017

For men with high serum prostate-specific antigen, multi-parametric magnetic resonance imaging (MP-MRI) is more sensitive but less specific than transrectal ultrasound guided prostate biopsy (TRUS-biopsy) for detecting clinically significant cancer, and can be used as a triage test to avoid unnecessary biopsy, according to a study published online in The Lancet.

Work-Related Stress May Be Tied to Certain Cancers

By January 17, 2017

Prolonged work-related stress in men has been tied to increased chances of cancer at five sites; lung, colon, rectal, stomach and lymphatic.

Outcomes Compared for Zoledronic Acid Use Every 12 Weeks vs. Every Four

January 04, 2017

Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, according to a study published in the January 3 issue of the Journal of the American Medical Association.

Research ID's Gene Mutations Which May Predict Lethal Prostate Cancer

December 19, 2016

The rate of germline BRCA1/2 and ATM mutations is significantly higher among patients with lethal prostate cancer (PCa) and is an independent predictor of lethal PCa, according to a study published online December 15 in European Urology.

Review Finds Consensus for MRI in Patients With Negative Biopsies

December 16, 2016

Magnetic resonance imaging (MRI) and MRI-targeted biopsies have a role in the diagnosis and treatment of patients with a prior negative prostate biopsy, according to a review published in the December issue of The Journal of Urology.

Androgen Deprivation as Prostate CA Therapy and Dementia Risk Examined

November 28, 2016

For men with prostate cancer, use of androgen deprivation therapy (ADT) seems not to be associated with dementia, according to a study published online in the Journal of Clinical Oncology.

Prostate MRI Should be Considered in Possible Repeat Biopsies, Say New Guidelines

November 18, 2016

In a consensus statement from the American Urological Association and Society of Abdominal Radiology, published in The Journal of Urology, guidelines are presented for prostate magnetic resonance imaging (MRI) in patients with negative biopsy.

Exercise Before and After Cancer Treatment May Bear Fruit for Patients

November 16, 2016

Exercising during and after cancer treatment is safe and improves quality of life, fitness, and physical functioning